Security key
036752202
- Security type / class
- Equity / PREFERRED STOCK
- Total 13F shares
- 1
- Total 13F value
- $57
- Share change
- 0
- SEC-reported price per share
- $57.00
- Number of holders
- 1
Report period
Q4 2023
Institutions
1
Top holders
1
ANTX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
AN2 Therapeutics, Inc. SEC filings
AN2 Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 036752202
Recent filing periods:
Ownership snapshot
Top reported holders of ANTX - ELEVANCE HEALTH INC - PREFERRED STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
RA CAPITAL MANAGEMENT, L.P.
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
0/15
Latest evidence
30 Sep 2023
13F
Highest disclosed value: $89,264,824
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
RA CAPITAL MANAGEMENT, L.P. has the largest disclosed position value at $89.26M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.
Disclosed position value
Top 5
RA CAPITAL MANAGEMENT, L.P.
$89.26M
TCG Crossover Management, LLC
$43.07M
BVF INC/IL
$25.15M
CITADEL ADVISORS LLC
$25.03M
Frazier Life Sciences Management,...
$22.33M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
—
denominator unverified
|
$89,264,824
5,551,295 shares
|
— | 30 Sep 2023 |
| TCG Crossover Management, LLC |
13F
Company
|
—
denominator unverified
|
$43,065,600
2,678,209 shares
|
— | 30 Sep 2023 |
| BVF INC/IL |
13F
Company
|
—
denominator unverified
|
$25,148,525
1,563,963 shares
|
— | 30 Sep 2023 |
| CITADEL ADVISORS LLC |
13F
Company
|
—
denominator unverified
|
$25,029,356
1,556,552 shares
|
— | 30 Sep 2023 |
| Frazier Life Sciences Management, L.P. |
13F
Company
|
—
denominator unverified
|
$22,333,335
1,388,889 shares
|
— | 30 Sep 2023 |
| Janus Henderson Group Ltd. |
13F
Company
|
—
denominator unverified
|
$22,146,816
1,388,950 shares
|
— | 30 Sep 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
1
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2023 vs Q1 2026 Across Filers
Q1 2026 holders
1
Q4 2023 holders
1
Holder diff
0
| Investor | Q1 2026 Shares | Q4 2023 Shares | Share Diff | Share Chg % | Q1 2026 value | Q4 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend